ABSTRACT The effects of 6/85-strain Mycoplasma gallisepticum (6/85MG) inoculation alone or in conjunction with a F-strain M. gallisepticum (FMG) overlay and its timing on the performance of commercial egg-laying hens were investigated. Control birds received sham inoculations at 10 wk of age. A second treated group of birds was inoculated with 6/85MG at 10 wk of age, a third treatment group of birds was inoculated with 6/85MG at 10 wk and received an overlay of FMG at 22 wk, and a fourth treatment group was inoculated with 6/85MG at 10 wk followed by a 45-wk overlay inoculation of FMG. Parameters investigated between 20 and 55 wk of age included BW, mortality, weekly and total egg production, egg weight, relative eggshell conductance, eggshell weight per unit of surface area, percentage shell weight, yolk/albumen ratio, and egg shape index. Hen age effects
INTRODUCTION
Mycoplasma gallisepticum (MG) infections have been shown to reduce the performance of commercial laying hens, leading to significant economic losses (Yoder and Hofstad, 1964; Domermuth et al., 1967; Mohammed et al., 1987; Patterson, 1994) . The F-strain of MG (FMG) is commonly used as an inoculum in the poultry industry but is known to depress the egg production (EP) of layers when administered at 10 or 22 wk of age (Branton et al., 1 This is journal No. J-11157 from the Mississippi Agricultural and Forestry Experiment station supported by MIS-321010. 2 Use of trade names in this publication does not imply endorsement by Mississippi Agricultural and Forestry Experiment Station of these products, nor similar ones not mentioned. 3 Corresponding author: dpeebles@poultry.msstate.edu 588 were reported for BW, egg weight, yolk/albumen ratio, and egg production. No treatment effects or hen age × treatment interactions were noted for those parameters except for yolk/albumen ratio, and no significant effects of any kind were noted for the remaining parameters examined. At wk 47, a significant treatment effect for yolk/albumen ratio was noted. The yolk/albumen ratio in the group of birds that received 6/85MG at 10 wk followed by an overlay of FMG at 22 wk was significantly lower than the sham control birds and those that were inoculated with 6/85MG at 10 wk followed by a 45-wk overlay inoculation of FMG. Prelay 6/85MG inoculations may be a suitable substitute for prelay FMG inoculations, and FMG overlays during lay on prelay 6/85MG inoculations may provide continual protection without eliciting any subsequent suppressive effects on performance.
2002). Burnham et al. (2002b) similarly reported that when commercial layers are inoculated with FMG at 12 wk of age, onset of lay is delayed. Furthermore, it was noted in that same report that 12-wk FMG inoculations led to delays in undersize EP, decreases in total EP, and declines in postpeak lay after 44 wk.
When administered prelay or at lay initiation, the 6/ 85-strain of MG (6/85MG) is less disruptive to layer EP than FMG, but it does not protect as well as FMG from the more virulent strains of MG (Branton et al., 2002) . More specifically, Branton et al. (2002) reported that a prelay (10 wk) 6/85MG inoculation had no significant impact on total EP or on various internal egg and eggshell parameters including egg weight, eggshell breaking strength, Haugh unit scores, eggshell pimpling incidence, and blood and meat spot incidences through 43 wk of age. There are possible benefits of using a prelay 6/85MG inoculation in conjunction with FMG inoculations during lay to effectively protect flocks against field strain MG infections, and also reducing possible subsequent depressions in EP due to a prelay FMG inoculation. This possible inoculation regimen may be commercially important because commercial operations may acquire flocks already inoculated with 6/85MG, but may also desire to continue using the FMG inoculation regimen familiar to them.
Therefore, the goal of this study was to investigate the effects of a 6/85MG inoculation prelay overlaid with FMG inoculation during lay on the performance of commercial layers. The performance parameters investigated included weekly and total EP, egg weight, and various internal egg and eggshell quality parameters from 20 to 55 wk of age.
MATERIALS AND METHODS

Pullet Housing and Management
In both trials, 1-d-old Hy-Line W-36 Leghorn pullets were obtained from a commercial hatchery certified free for MG and MS (USDA-APHIS-VS, 2003). Until 10 wk of age, birds were raised on new soft wood shavings, in a 5.5 × 6.1 m section of a conventional house, at a USDA facility. Initial flock density was 0.034 m 2 /bird. In the conventional house, a daily artificial lighting schedule followed a 13L:11D cycle. One 75-W light bulb was used to illuminate each 8.4 cm 2 of floor space, providing a 35.5 lx intensity at bird level.
At 10 d of age, all pullets were vaccinated for infectious bursal disease. At 12 d and at 4 wk of age, they were vaccinated against Newcastle disease and infectious bronchitis viruses via drinking water. At 5 wk of age, choanal cleft swabs were taken (Branton et al., 1984) , and chicks were bled from a wing vein and tested for MG/MS antibodies using serum plate agglutination (SPA) and hemagglutinin inhibition (HI) tests (Kleven, 1998) . Choanal cleft swabs were placed into tubes containing Frey's broth medium (Frey et al., 1968) supplemented with thallium acetate and 10 6 IU of penicillin-G/mL. Tubes were incubated at 37°C. Colonies with morphology suggestive of Mycoplasma species were examined by an agar plate fluorescent antibody (FA) method (Baas and Jasper, 1972) .
Layer Housing and Management
At 10 wk of age, 11 pullets were randomly assigned to each of 16 negative pressure biological units. The units were located in a previously described USDA poultry disease isolation facility (Branton and Simmons, 1992) . All birds were wing-banded for purposes of identification and individual data collection. At initiation of lay, the number of hens in each treatment unit was reduced to 10, resulting in a bird density of 0.116 m 2 /bird. The temperature inside each biological unit was maintained at 25°C. Four negative pressure units were assigned to each of 4 treatments, and each treatment was represented by 1 row of the 4 units. In trial II, the location of treatments within the isolation facility was different from that in trial I to assure environmental randomization between trials. Table 1 . Titers used in 6/85MG at 10 wk (6/85MG-10), 6/85MG at 10 and FMG at 22 wk , and 6/85MG at 10 and FMG at 45 wk (6/85MG-10, FMG-45) of age inocula in trials I and II
Inoculum
Trial 
Pullet and Layer Diets
For the duration of each trial, chickens had ad libitum access to feed and water. Birds received standard diets that met or exceeded National Research Council (1994) recommendations. Diets were formulated according to the age of the birds and included the following: starter (0 to 6 wk), grower (6 to 12 wk), developer (12 to 18 wk), prelay (18 to 20 wk), and layer (20 to 60 wk). Ingredient percentages, calculated, and determined analysis of these diets were described by Burnham et al. (2002b) .
6/85MG and FMG Inoculation
Control birds received sham inoculations in the right eye with 0.04 mL of sterile Frey's broth media at 10 wk of age. A second treated group of birds was inoculated with a 24-h broth culture of 6/85MG at 10 wk of age (6/ 85MG-10). In a third treatment group, birds inoculated with 6/85MG at 10 wk received an overlay of FMG at 22 wk (6/85MG-10, FMG-22), and a fourth treatment group was inoculated with 6/85MG at 10 wk followed by a 45-wk overlay inoculation of FMG (6/85MG-10, FMG-45). Mycoplasma gallisepticum organisms were advanced after being received from S. H. Kleven (University of Georgia, Athens, GA) at the 212th passage. Titers of the inocula are presented in Table 1 .
Mycoplasma Detection
In each trial, at 58 wk of age, 3 randomly selected hens from each replicate unit in each of the 4 treatment groups were bled from a wing vein and were swabbed to test for the presence of MG. Testing procedures at this time were as described for those at 5 wk of age.
Data Collection
In each trial individual BW were recorded at 20, 24, 32, 43, and 47 wk. Weekly EP was recorded daily and analyzed weekly from wk 20 to 54 and was expressed as percent hen-day production. Furthermore, the total number of eggs produced per hen (total hen EP) from wk 20 to 54 was determined. Total hen EP was calculated as total daily numbers of eggs produced as a percentage of total daily numbers of hens for each replicate group (pen) over the entire 20-to 54-wk production period. Mortality was recorded daily and was expressed as a percentage of the total number of birds in each pen.
In each trial, egg weight (EW) was determined weekly from 23 through 55 wk, and at wk 24, 32, 43, and 47 eggshell weight per unit of surface area (SWUSA), yolk/ albumen ratio (YAR), and percentage eggshell weight (PSW) were determined. Furthermore, at wk 27, 31, 49, and 53 of trial II, relative eggshell conductance and egg shape index were determined. Relative eggshell conductance and egg shape index were determined according to the procedures of Peebles et al. (1994) and Richards and Swanson (1965) , respectively. For determination of the above mentioned internal egg and eggshell quality parameters (SWUSA, YAR, PSW, relative eggshell conductance, and egg shape index) a total of 10 eggs were collected and used from each replicate unit. If less than 10 eggs were collected on a given day, the rest were collected the following day of the same week. Nevertheless, determinations were made on the same day that eggs were collected. The SWUSA of eggs was determined using the following formula: SWUSA = [eggshell weight (mg)/ eggshell surface area (cm 2 )], where eggshell surface area = 3.9782 × EW 0.7056 (Carter, 1975) . Eggshell weight was determined according to the procedures described by Brake et al. (1984) . Relative eggshell (dried shell plus membranes) weights were expressed as percentages of total EW.
Statistical Analysis
A completely randomized experimental design, with trial as a block, was used. Data before wk 22 (age interval I), from wk 22 through 44 (age interval II), and from wk 45 through 55 (age interval III) were analyzed separately. The data of both trials were pooled then analyzed together. Therefore, the results from both trials were not reported independently, but were reported over both trials. Trial was considered as a random effect. All data within each age interval were subjected to a repeated measures analysis if parameters were examined at multiple age periods in an age interval. Otherwise, data obtained at only 1 age period within an age interval were subjected to 1-way ANOVA.
In the first age interval, the control and 6/85MG-10 treatment groups were compared. In the second age interval, controls and those having had 6/85MG-10 and 6/ 85MG-10, FMG-22 inoculations were compared. In the third age interval, control, 6/85MG-10, 6/85MG-10, FMG-22, and 6/85MG-10, FMG-45 groups were compared. Individual sample data within each of these replicate units were averaged before analysis. Least-squares means were compared in the event of significant global effects (Steel and Torrie, 1980) . Global effects and differ- ences among least-squared means were considered significant at P ≤ 0.05. All data were analyzed using the MIXED procedure of SAS software (SAS Institute, 2003) .
RESULTS
All initial cultures of Mycoplasma as well as HI and SPA test results were obtained from pullets at 5 wk of age and were negative for MG and MS. Samples of serum obtained from control birds at 58 wk of age were SPA and HI negative for MG, whereas the same tests were positive for MG in the 6/85MG and FMG inoculated hens. Hens were considered to be free of MG when no detectable HI titers were exhibited, and FA culture results showed no MG growth. All MG inoculated hens showed HI titers ≤1:80 (geometric mean of 80.0), and were MG-positive (positive for MG fluorescence) and MS-negative (negative for MS fluorescence) using FA tests.
No significant age or treatment main effects or age × treatment interactions were found for bird mortality and BW in any of the 3 age intervals examined. However, for reference, mean BW values at the various age periods examined in each age interval are provided in Figure 1 . Also for reference, mean BW values for each treatment group within each age interval are provided in Table 2 . There were significant age main effects for weekly EP in intervals II (P ≤ 0.001) and III (P ≤ 0.001), as shown in Figure 2 . Weekly EP was significantly increased between wk 22 and 23 and between wk 23 and 25 in interval II. In that interval EP did not change significantly between wk 25 and 44. Furthermore, weekly EP significantly decreased at wk 47, increased at wk 49, and then decreased again at wk 50 and 54 in interval III. In intervals II and III there were no significant treatment main effects or age × treatment interaction for weekly EP. There were no significant main effects due to treatment or age, and there was no age × treatment interaction for weekly EP in interval I. Furthermore, total EP across lay (wk 20-54; intervals Table 2 . Body weight in control, 6/85MG at 10 wk (6/85MG-10), 6/ 85MG at 10 and FMG at 22 wk (6/85MG-10, FMG-22), and 6/85MG at 10 and FMG at 45 wk (6/85MG-10, FMG-45) treatment groups in hen age intervals I (20 wk), II (24, 32, and 43 wk) I, II, and III) was not significantly affected by treatment. However, for reference, total EP across lay for the control; 6/85MG-10; 6/85MG-10, FMG-22; and 6/85MG-10, FMG-45 treatment groups was 75.4, 71.7, 74.2, and 75.0%, respectively (pooled SEM = 2.60). Significant age main effects were found for EW during intervals II (P ≤ 0.0001) and III (P ≤ 0.003) as shown in Figure 3 . Egg weight increased as birds progressively increased in age from 23 to 44 wk (interval II), and again from 45 to 55 wk (interval III). Significant increases in EW in interval II occurred between wk 25 and 26, 29 and 31, 33 and 34, 36 and 37, 37 and 40, and 39 and 44. Also, significant increases in EW occurred in interval III between wk 49 and 50. During intervals II and III, no significant treatment main effects or age × treatment interactions were found. Nevertheless, mean EW values for each treatment group within both age intervals are provided in Table 3 . There were also no significant effects of any kind for relative eggshell conductance, SWUSA, or PSW in intervals II and III or for egg shape index in interval II. However, there was a significant age main effect (P ≤ 0.04) for egg shape index in interval III. Egg Figure 2 . Weekly egg production in hen age intervals I (20 and 21 wk), II (22 to 44 wk), and III (45 to 54 wk). Sixteen replicate units were used for calculation of the mean at each age period within each hen age interval. The SEM values, based on pooled estimate of variance, for age intervals I, II, and III were 8.93, 3.76, and 3.76, respectively.
shape index decreased between wk 49 and 53. Egg shape index at wk 49 and 53 was 76.0 and 75.3, respectively (pooled SEM = 0.36). There was no significant treatment main effect or age × treatment interaction for egg shape index in interval III.
A significant (P ≤ 0.008) age main effect during interval II was found for YAR. Mean YAR at wk 24, 32, and 43 was 0.387, 0.434, and 0.466, respectively (pooled SEM = 0.015). Yolk/albumen ratio increased significantly between successive time periods. Conversely, in interval III (wk 47), a significant (P ≤ 0.04) treatment main effect for YAR was noted (Table 3) . The 6/85MG-10, FMG-22 group was significantly lower than the control and 6/85MG-10, FMG-45 groups, with the 6/85MG-10 group intermediate. However, there was no treatment main affect or age × treatment interaction for YAR in interval II. For reference, mean YAR values for each treatment group within interval II are also provided in Table 3 .
DISCUSSION
At the end (55 wk of age) of both trials in this study, SPA, HI, and FA tests verified systemic infections in 6/ 85MG and FMG inoculated hens. Conversely, sham-inoculated birds remained free of M. gallisepticum throughout the study. Mycoplasma gallisepticum manifestations generally occur in the respiratory system and lesions can become extensive when complicated by other bacteria. Also, environmental factors such as dust and ammonia, in conjunction with intensive rearing or stress, crowding, cold weather, live virus vaccination, or natural virus infection may be important in the incidence and severity of lesions (Jordan, 1972; Springer et al., 1974; Jordan, 1985) . However, mycoplasma infection is often subclinical or mild when there are no secondary infections (Kerr and Olsen, 1967) . Birds in both trials were housed in biological isolation units from 10 wk of age through the remainder of the study, where natural infections and other environmental stressors common in commercial operations were eliminated. As a result, the 6/85MG and FMG inoculated hens exhibited no outward pathological symptoms.
In a previous study by Burnham et al. (2002b) , weekly EP was delayed 1 wk in each of 2 experimental trials, whereas total EP was reduced in only 1 of the 2 trials in layers inoculated with the F-strain of MG at 12 wk of age. The decrease in total EP in that trial became apparent at each week after wk 42. Burnham et al. (2002a) later suggested that alterations in the performance and egg characteristics of the layers examined were related to mutual functional disturbances in the liver, ovary, and oviduct, without any noticeable sign of intestinal changes. This suggestion was supported by results showing a reduction in ripe ovarian follicle numbers as well as ovarian follicle size, and increased incidences of fatty liver hemor- Table 3 . Egg weight (EW) in hen age intervals II (23 to 44 wk) and III (45 to 55 wk), and yolk/albumen ratio (YAR) in hen age intervals II (24, 32, and 43 wk) and III (47 wk) for control, 6/85MG at 10 wk (6/ 85MG-10), 6/85MG at 10 and FMG at 22 wk (6/85MG-10, FMG-22), and 6/85MG at 10 and FMG at 45 wk Treatment means for YAR within age interval III with no common superscript differ significantly (P ≤ 0.05). rhagic syndrome in birds that demonstrated depressed performance subsequent to FMG inoculation at 12 wk of age. However, previous findings by Evans and Hafez (1992) have indicated that while providing protection against field strain MG (i.e., R-strain) infections, 6/85MG inoculations at 2 wk of age did not suppress growth in broiler chickens. Furthermore, Branton et al. (2002) showed that 6/85MG had no impact on commercial layer performance or egg quality when inoculated prelay (10 wk of age). These results suggest that using 6/85MG rather than FMG prelay may achieve the same level of protection against field strain MG infections, while eliminating the noted negative effects of prelay FMG vaccines on EP (weekly and total).
In accordance with the results reported by Branton et al. (2002) , inoculation of commercial layers with 6/85MG at 10 wk had no significant effect on weekly or total EP in the current study. Furthermore, F-strain MG overlays at 22 and 45 wk of age on the 10-wk 6/85MG inoculation had no significant effect on weekly or total EP. These results confirm the hypothesis that prelay 6/85MG inoculations may be a suitable substitute for prelay FMG inoculations and that FMG overlays during lay on prelay 6/ 85MG inoculations may also provide continual protection without eliciting any subsequent suppressive effects on performance.
In a companion report by Burnham et al. (2003) , in which egg yolk composition was altered by 12-wk FMG inoculations, it was also concluded that the alterations in EP were associated with colonization of the liver by FMG with subsequent functional disturbances in the metabolism of liver lipids and the deposition of circulating lipids in the ovarian follicles. Burnham et al. (2002b) showed that the inoculation of FMG at 12 wk did not significantly affect EW and all internal egg and eggshell quality param-eters investigated except for PSW. However, PSW was increased only at wk 24 and 34 in response to the 12-wk FMG inoculation. Despite the refractoriness of the internal egg and eggshell quality parameters to the prelay FMG inoculation, Burnham et al. (2002b) noted a significant decline in EP after wk 44, which culminated in a significant decrease in total EP. Conversely, although this current study also showed a lack of significant treatment effects on EW and egg and eggshell quality, except for a singular effect on YAR, it did not indicate a significant decrease in EP late in lay or in total EP in response to treatments administered. This indicates a protective response from the prelay 6/85MG inoculation and supports the Branton et al. (2002) study that indicates a lack of impact on EP when using a 6/85MG inoculation regimen. It also indicates that the overlay of FMG on the 6/85MG prelay inoculation exerts no further negative effect on performance as well as overall egg and eggshell quality.
In conclusion, these results establish that prelay 6/ 85MG inoculations may be a suitable substitute for prelay FMG inoculations and that FMG overlays during lay on prelay 6/85MG inoculations may also provide continual protection without eliciting any subsequent suppressive effects on performance. Because these birds were housed in isolation units, these results do not preclude the possibility that different or greater performance and physiological effects may occur in birds infected prelay, at lay onset, or late in lay with 6/85MG or FMG alone or in combination, when housed in facilities where there are increased levels of environmental stress.
